Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

7.445 +0.145 (+1.99%)
Streaming Delayed Price Updated: 10:54 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Announces Leadership Changes
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.